Egle Therapeutics
- Biotech or pharma, therapeutic R&D
Spin out of the Institut Curie backed by a 40M€ Series A plus a research collaboration with Takeda, Egle Therapeutics is a clinical stage biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells. The lead asset in oncology EGL-001 is in phase 1/2 clinical trail as a single agent and in combination with Keytruda. EGL-003 the lead asset for the treatment of autoimmune disease will be entering the clinic in 2H2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}